Serotonin Antagonism and Serotonin Antagonists in Pregnancy: Role of Ketanserin

Steyn, D.W.; Odendaal, Hein J.

doi:10.1097/00006254-200009000-00024

Cited by 20 publications

(7 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rate of persisting severe hypertension using ketanserin in our study was 73.3%. This percentage is higher than mentioned in literature, which ranges from 18 to 32% [6,9,12], despite comparable dosages [7,13]. It is difficult to compare our results with the results of other reports because of the heterogenity between studies in definitions of complications, demographic characteristics and number of women studied.…”

Section: Commentcontrasting

confidence: 72%

Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial

Bijvank

Visser

Duvekot

et al. 2015

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Section: Commentcontrasting

confidence: 72%

Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial

Bijvank

Visser

Duvekot

et al. 2015

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

“…Ketanserin is a selective S2 receptor-blocking agent that has been used in the nonpregnant population. Based on the data available from Australia and South Africa, it may be safe to use in pregnancy and useful in treatment of chronic hypertension in pregnancy, preeclampsia, and HELLP syndrome [133, 134]. FDA has not approved Ketanserin for use in United States.…”

Section: Choice Of Antihypertensive Drugsmentioning

confidence: 99%

A Comprehensive Review of Hypertension in Pregnancy

Mustafa

Ahmed

Gupta

et al. 2012

Journal of Pregnancy

229

203

View full text Add to dashboard Cite

Hypertension is the most common medical disorder encountered during pregnancy. Hypertensive disorders are one of the major causes of pregnancy-related maternal deaths in the United States. We will present a comprehensive update of the literature pertinent to hypertension in pregnancy. The paper begins by defining and classifying hypertensive disorders in pregnancy. The normal vascular and renal physiological changes which occur during pregnancy are detailed. We will summarize the intriguing aspects of pathophysiology of preeclampsia, emphasizing on recent advances in this field. The existing diagnostic tools and the tests which have been proposed for screening preeclampsia are comprehensively described. We also highlight the short- and long-term implications of preeclampsia. Finally, we review the current management guidelines, goals of treatment and describe the potential risks and benefits associated with various antihypertensive drug classes. Preeclampsia still remains an enigma, and the present management focuses on monitoring and treatment of its manifestations. We are hopeful that this in depth critique will stimulate the blossoming research in the field and assist practitioners to identify women at risk and more effectively treat affected individuals.

show abstract

“…Ketanserin has not been found to be teratogenic in animals or humans and has been studied primarily in Australia and South Africa in small trials, which suggest that it may be safe and useful in the treatment of chronic hypertension in pregnancy, preeclampsia, and hemolysis elevation of liver enzymes, low platelets syndrome. 76,77 Ketanserin has not been Food and Drug Administration approved in the United States.…”

Section: Serotonin 2 Receptor Blockersmentioning

confidence: 99%